For clinical researchers, getting to a finished protocol is a delicate art in navigating research, regulatory precedence, and institutional knowledge. And complexity continues to grow - more regulations, more endpoints per trial, more amendments, and more options (in-person or remote assessments). The clinical protocol has become everything but the kitchen sink. So how can we simplify while maintaining data quality and integrity? We need reliable recommendations so that we can make decisions without wading through every piece of research and data available.
ICON knows that ontologies are a great way to organize large datasets to build insights through computation. ICON’s Atlas™ platform organizes >3.5k Digital Health Technologies (DHTs) across measures (passively-monitored COAs and digital biomarkers), medical conditions, and vendors. While DHTs are one piece of the puzzle, holistic protocol design requires more breadth. When selecting which COAs will represent study endpoints, a questionnaire, standardized task, DHT, or a combination thereof could be used to measure the same or related outcome:
And yet, no single resource exists to compare them side-by-side to help researchers pick the right tool for the job. Thus, we started brainstorming ways to expand the precision measurement capabilities of Atlas Network to include traditional, actively collected COAs.
ICON-sponsored MAPI Research Trust’s ePROVIDE™ database maintains the world’s largest library of >5k actively collected COAs. Turns out, five of the data elements in ePROVIDE™ and Atlas™ can be perfectly overlaid: Therapeutic area(s), medical condition(s), concepts of interest/domains, measures, and populations (Fig 2). These data elements create a backbone for a shared framework — or what we call “an aligned ontology”:
We validated this conceptual alignment and selected atopic dermatitis as a proof-of-concept. As described in our paper published in Nature’s npj Digital Medicine, this framework allows researchers to compare all relevant actively-collected and passively-monitored COAs and pick the best one for their study. Together with our co-authors we imagined how this aligned ontology could answer these questions:
- Which questionnaire(s), DHT(s), and standardized tasks have been used to measure COAs for atopic dermatitis?
- How has scratching behavior been measured actively and/or passively?
- Which tool(s) are well validated for my target population?
- Which tool(s) have data robust enough to support regulatory approval and reimbursement?
As well as practical considerations, such as:
- Can the tool be deployed (e.g., shipped, translated, operated, etc.) in the geographic region(s) needed for my trial?
Both actively-collected and passive-monitoring COAs can be critical components to bringing patient-centred treatments to market and aligning them is a big step in helping the industry select the right tool for the job — such as picking a DHT to passively collect data when a PRO might be difficult to administer or using both to contextualize passively-collected data to a participant’s reported experience.
This new way to research, identify, and select fit-for-purpose measures with confidence will reduce the number of endpoints in clinical studies without sacrificing quality and data integrity. Simpler protocols lessen the burden on participants and sites, can increase response rates and retention, and reduce issues with missing data along with many other downstream improvements to effort and cost.
Now imagine this aligned ontology persisted as a living repository mapping evidence collected as these decisions are made, the trials are conducted, and the results are published. Additional datasets - like imaging, labs, or real-world data - can be added and aligned. This dataset could be used to train language models and/or generative AI, leading to insights and predictive recommendations for better drug discovery and development. This is one way our industry gets closer to the vision of precision measures for patient-centered drug development.
Blog authored by Courtney Webster, Compliance, ICON. Originally written for HumanFirst, a company acquired by Icon in january 2024.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel